Active	Status	Sponsor type	Region	Phase	Filter
6 Active 2 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Skinner, Eila C
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
Cahn, David J
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
Aggers, Deborah
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin	Recruiting	3	190	Japan, US, RoW	Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer	12/27	12/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30